- Literature - May 24
UChicago to honor historian Black, theater director Bogart at Convocation - Agronomy - May 24
Diagnostic labs analyze anything from bugs to toenails - Medicine - May 24
UCLA launches first face transplantation program in western U.S - Administration - May 24
’Click It or Ticket’ Enforcement on Penn Campus - Medicine - May 24
Hormone Plays Surprise Role in Fighting Skin Infections - Pedagogy - May 24
Two SEAS profs envision the next big ideas in teaching and learning - Environmental Sciences - May 24
Columbia's Manhattanville Campus Earns LEED Platinum for Neighborhood Plan - Literature - May 24
Historic Greek Theatre safe, sound and superb after upgrades - Law - May 24
Latest UT/Texas Tribune Poll: Tax Pledge Issue Reveals Conservative Divide - Computer Science - May 24
SDSC to Host "Summer Institute" Supercomputer Workshop August 6-10 - Earth Sciences - May 24
SDSC to Host Summer Institute for Geosciences August 6-10 - Arts - May 24
Center for the Art of Performance at UCLA announces 2012-13 season
Administration
Chemistry
Physics
Computer Science
Environmental Sciences
Earth Sciences
Life Sciences
Medicine
Business
Law
Literature
History
Arts
» » more
Let’s do the twist: Spiral proteins are efficient gene delivery agents

Illinois researchers developed spiral polypeptides that can deliver DNA segments to cells with high efficiency and relatively low toxicity, a step toward clinical gene therapy. The team, from left, postdoctoral researchers Lichen Yin and Dong Li; Fei Wang, a of cell and developmental biology; Jianjun Cheng, a of materials science and engineering; and Nathan Gabrielson, a postdoctoral researcher.
CHAMPAIGN, Ill. -- Clinical gene therapy may be one step closer, thanks to a new twist on an old class of molecules.
A group of University of Illinois researchers, led by professors Jianjun Cheng and Fei Wang, have demonstrated that short spiral-shaped proteins can efficiently deliver DNA segments to cells. The team published its work in the journal Angewandte Chemie.
“The main idea is these are new materials that could potentially be used for clinical gene therapy,” said Cheng, a professor of materials science and engineering, of chemistry and of bioengineering.
Researchers have been exploring two main pathways for gene delivery: modified viruses and nonviral agents such as synthetic polymers or lipids. The challenge has been to address both toxicity and efficiency. Polypeptides, or short protein chains, are attractive materials because they are biocompatible, fine-tunable and small.
“There are very good in vitrotransfection agents available, but we cannot use them in vivo because of their toxicity or because some of the complexes are too large,” Cheng said. “Using our polypeptides, we can control the size down to the 200 nanometer range, which makes it a very interesting delivery system for in vivo applications.”
A polypeptide called poly-L-lysine (PLL) was an early contender in gene delivery studies. PLL has positively charged side chains - molecular structures that stem from each amino acid link in the polypeptide chain - so it is soluble in the watery cellular environment.
However, PLL gradually fell into disuse because of its limited ability to deliver genes to the inside of cells, a process called transfection, and its high toxicity. Cheng postulated that PLL’s low efficiency could be a function of its globular shape, as polypeptides with charged side chains tend to adopt a random coil structure, instead of a more orderly spiral helix.
“We never studied the connections of conformation with transfection efficiency, because we were never able to synthetically make materials containing both cationic charge and a high percentage of helical structures,” Cheng said. “This paper demonstrated for the first time that helicity has a huge impact on transfection efficiencies.”
Earlier this year, Cheng’s group developed a method of making helical polypeptides with positively charged side chains. To test whether a helical polypeptide could be an efficient gene delivery agent, the group assembled a library of 31 helical polypeptides that are stable over a broad pH range and can bond to DNA for delivery. Most of them outperformed PLL and a few outstripped a leading commercial agent called polyethyleneimine (PEI), notorious for its toxicity although it is highly efficient. The helical molecules even worked on some of the hardest cells to transfect: stem cells and fibroblast cells.
“People kind of gave up on polypeptide-based materials for gene deliveries because PLL had low efficiency and high toxicity,” Cheng said. “The polypeptide that we designed, synthesized and used in this study has very high efficiency and also well-controlled toxicities. With a modified helical polypeptide, we demonstrated that we can outperform many commercial agents.”
The polypeptides Cheng and his co-workers developed can adopt helical shapes because the side chains are longer, so that the positive charges do not interfere with the protein’s winding. The positive charges readily bind to negatively charged DNA, forming complexes that are internalized into cellular compartments called endosomes. The helical structures rupture the endosomal membranes, letting the DNA escape into the cell.
To confirm that the spiral polypeptide shape is the key to transfection, the researchers then synthesized two batches of the most efficient polypeptide: one batch with a helical shape, one with the usual random coil. The helical polypeptide far exceeded the random-coil polypeptide in both efficiency and stability.
“This demonstrates that the helicity is very important, because the polymer has exactly the same chemical makeup; the only difference is the structure,” said Cheng, who also is associated with the Institute for Genomic Biology and the Beckman Institute for Advanced Science and Technology, both at the U. of I.
Next, the researchers plan to further explore their helical polypeptides’ properties, especially their cell-penetrating abilities. They hope to control sequence and structure with precision for specific applications, including gene delivery, drug delivery, cell-membrane penetration and antimicrobial action.
Fei Wang is a professor of cell and development biology and of bioengineering. Postdoctoral researchers Nathan Gabrielson, Lichen Yin and Dong Li and graduate student Hua Lu were co-authors of the paper.
Last job offers
- Law - 21.5
Doctoral Programme at the Law School of the University of Basel - Life Sciences - 18.4
Senior Expert - Genetic Biomarker Oncology (PhD) m/f - Business - 22.5
Research Associate - Civil Engineering - 15.5
Research Specialist - Beckman Institute (A1200274) - Life Sciences - 15.5
Staff Research Associate II - Medicine - 12.5
Research Specialist - Business - 4.5
Assistant Professor of Economics, Non Tenure Track, Fall 2012 - Business - 3.5
Post Doctoral Fellow






» Share this page: